Telomir Pharmaceuticals, INC

Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data showing Telomir-Zn restored insulin sensitivity and improved glucose homeostasis in a Type 2 diabetes zebrafish model.

Telomir Pharmaceuticals has appointed Andriy Mushak as its new fractional Chief Financial Officer, effective June 6, 2026.

Telomir Pharmaceuticals announced the publication of a peer-reviewed preclinical study detailing positive results for Telomir-Zn in a Wilsons disease zebrafish model, showing improved survival and multiple endpoint benefits.

Telomir Pharmaceuticals announced FDA clearance of its Investigational New Drug application for Telomir-Zn, paving the way for a Phase 1/2 trial in triple-negative breast cancer.

Telomir Pharmaceuticals, Inc. has completed the acquisition of TELI Pharmaceuticals, Inc., consolidating global rights for its Telomir-1 (Telomir-Zn) platform.

Telomir Pharmaceuticals, Inc. announced it has regained compliance with Nasdaq Listing Rule 5620(a) after holding its 2025 Annual Meeting of Shareholders.

Telomir Pharmaceuticals reports reduced operating costs and net loss in Q1 2026, following the completion of its merger with TELI and securing future funding commitments.

Telomir Pharmaceuticals reported reduced net losses and increased cash reserves, driven by recent equity financings, while announcing a binding LOI to acquire worldwide rights for its lead candidate, Telomir-1.

Telomir Pharmaceuticals reported a significant net loss in Q2 2025, driven by increased stock-based compensation, while advancing multiple preclinical programs and securing new equity financing.

Telomir Pharmaceuticals reports a net loss for Q1 2025 while highlighting preclinical study results for Telomir-1 in various age-related and other conditions.

Telomir Pharmaceuticals reported a net loss of $13.6 million for the nine months ended September 30, 2024, and expressed substantial doubt about its ability to continue as a going concern.

Telomir Pharmaceuticals reported its second quarter 2024 financial results, marked by increased operating expenses and a significant net loss, alongside major changes in its executive leadership and board composition.

Telomir Pharmaceuticals, a preclinical-stage biotech, reports progress on its lead compound Telomir-1 and announces a merger with TELI Pharmaceuticals to consolidate global intellectual property rights, despite ongoing net losses and a going concern warning.

Telomir Pharmaceuticals details its 2024 financial results and provides an update on the development of its lead drug candidate, Telomir-1, focusing on age-related diseases and metal ion regulation.

Telomir Pharmaceuticals' 10-K filing details their pre-clinical development of TELOMIR-1, focusing on osteoarthritis, hemochromatosis, and post-chemotherapy recovery.

Matthew Pratt Whalen, a Director of Telomir Pharmaceuticals, Inc., received 50,000 shares of common stock on April 16, 2026.

Edward Clouston Macpherson, a Director of Telomir Pharmaceuticals, Inc., received 50,000 shares of common stock on April 16, 2026.

Giudice Matthew Paul Del, a Director of Telomir Pharmaceuticals, Inc., received 50,000 shares of common stock on April 16, 2026.

Telomir Pharmaceuticals CEO Erez Aminov cancelled existing stock options in exchange for new grants with lower exercise prices.

Director Matthew Pratt Whalen cancelled existing stock options in exchange for new options with a lower exercise price.

Director Edward Clouston MacPherson cancelled existing stock options to receive new options with a lower exercise price.

Telomir Pharmaceuticals, Inc. has issued a proxy statement detailing its upcoming Annual Meeting of Shareholders, scheduled for September 11, 2026, to elect directors, ratify auditor appointment, and address other business.

John Paul DeJoria, through his family trust, has disclosed a 9.438% beneficial ownership stake in Telomir Pharmaceuticals, Inc.

John Paul DeJoria, through his family trust and individually, has reported a 5.5% beneficial ownership stake in Telomir Pharmaceuticals, Inc.